<Version>
  <xmlSource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Quality Measures Clearinghouse (NQMC).</xmlSource>
  <Section SecID="560" OrdBy="10" Name="General">
    <Field FieldID="11" OrdBy="20" ID="561" Name="Title" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Inflammatory bowel disease (IBD): percentage of patients aged 18 years and older with a diagnosis of IBD who have been managed by corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills that have been prescribed corticosteroid sparing therapy within the last 12 months.&lt;/div&gt;" />
    </Field>
    <Field FieldID="1" OrdBy="30" ID="562" Name="Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American Gastroenterological Association (AGA). Inflammatory bowel disease (IBD): preventive care: corticosteroid sparing therapy. Bethesda (MD): American Gastroenterological Association (AGA); 2015 Dec 18. 7 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
  </Section>
  <Section SecID="563" OrdBy="40" Name="Measure Domain">
    <Field FieldID="3025" OrdBy="50" ID="564" Name="Primary Measure Domain" Type="picklist-one">
      <FieldValue Value="Clinical Quality Measures: Process" />
    </Field>
    <Field FieldID="3026" OrdBy="60" ID="565" Name="Secondary Measure Domain" Type="picklist-one">
      <FieldValue Value="Does not apply to this measure" />
    </Field>
  </Section>
  <Section SecID="566" OrdBy="70" Name="Brief Abstract">
    <Field FieldID="34" OrdBy="80" ID="567" Name="Description" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This measure is used to assess the percentage of patients aged 18 years and older with a diagnosis of inflammatory bowel disease (IBD) who have been managed by corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills that have been prescribed corticosteroid sparing therapy within the last 12 months.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="21" OrdBy="90" ID="568" Name="Rationale" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Thirty to forty percent of patients with moderate to severe inflammatory bowel disease (IBD) have steroid dependent disease. That means that they are unable to taper off steroids without experiencing a flare up (Crohn's &amp;amp; Colitis Foundation of America [CCFA], 2009). A retrospective study examined whether the treatment of Crohn's disease (CD) and ulcerative colitis (UC) with immunosuppressant medications was associated with an increased risk of death prior to anti-TNF (tumor necrosis factor) therapies. The authors found that patients with both CD and UC are at increased risk of death during periods of current corticosteroid use. In contrast, current treatment with thiopurines was not associated with an increased risk of death (Lewis et al., 2008). Similar findings were reached after an additional 5 years of follow-up in this patient population using multivariate logistic regression analyses which demonstrated a significant increase in mortality risk associated with chronic corticosteroid therapy, Hazard Ratio-2.14 (Lichtenstein et al., 2012).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Clinical Recommendation Statements&lt;/strong&gt;: &lt;/p&gt;&#xD;&#xA;&lt;p&gt;Long-term treatment with corticosteroids is undesirable. Patients with chronic active corticosteroid-dependent disease (either CD or UC) should be treated with azathioprine (AZA) 2.0 to 3.0 mg/kg/day or 6-mercaptopurine (6-MP) 1.0 to 1.5 mg/kg/day in an effort to lower or preferably eliminate corticosteroid use. Infliximab is another option in this situation, as is combination infliximab/antimetabolite therapy (Lichtenstein et al., &quot;Corticosteroids,&quot; 2006).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Individual patients with either CD or UC who experience a severe flare of disease requiring corticosteroid treatment or require retreatment during the year with another course of corticosteroids should be considered for initiation of therapy with AZA 2.0 to 3.0 mg/kg/day or 6-MP 1.1 to 1.5 mg/kg/day in an effort to avoid future corticosteroid use. Infliximab is another option in this situation, as is combination infliximab/antimetabolite therapy (Lichtenstein et al., &quot;Corticosteroids,&quot; 2006). &lt;/p&gt;&#xD;&#xA;&lt;p&gt;Conventional corticosteroids are not efficacious in maintenance treatment of patients with CD or patients with UC (Lichtenstein et al., &quot;Corticosteroids,&quot; 2006).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Corticosteroids should not be used to maintain remission (Travis et al., 2006).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Conventional corticosteroids should not be used as long-term agents to prevent relapse of CD. Budesonide at a dose of 6 mg/day reduces the time to relapse in ileal and/or right colonic disease, but does not provide significant maintenance benefits after 6 months. Azathioprine/6-mercaptopurine and methotrexate have demonstrable maintenance benefits after inductive therapy with corticosteroids (Lichtenstein et al., 2009).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This is the first report from the TREAT Registry, a large, prospective, observational research program designed to address the long term safety of medications, including infliximab, for the treatment of CD. After adjustment for confounding factors including disease severity and the use of other medications, the risk for serious infection or death with infliximab use was similar to that observed with the use of conventional immunomodulators, and was not higher than the overall incidence of serious infections among all CD patients. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;The use of prednisone was a strong independent risk factor for both serious infection and death. Likewise, the use of narcotic analgesics also was associated with a significantly increased risk for serious infection (Lichtenstein et al., &quot;Serious infections,&quot; 2006) Additionally, recently published American Gastroenterological Association (AGA) guidelines for Crohn's disease recommend using anti-TNF [tumor necrosis factor] alpha drugs to induce remission in patients with moderately severe Crohn's disease (Terdiman et al., 2013).&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="3500" OrdBy="100" ID="569" Name="Evidence for Rationale" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American Gastroenterological Association (AGA). Inflammatory bowel disease (IBD): preventive care: corticosteroid sparing therapy. Bethesda (MD): American Gastroenterological Association (AGA); 2015 Dec 18. 7 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Crohn’s &amp; Colitis Foundation of America (CCFA). Corticosteroids. [internet]. New York (NY): Crohn’s &amp; Colitis Foundation of America (CCFA); 2009 Jan 16.&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lewis JD, Gelfand JM, Troxel AB, Forde KA, Newcomb C, Kim H, Margolis DJ, Strom BL. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol. 2008 Jun;103(6):1428-35; quiz 1436. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18494836&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006 Mar;130(3):935-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16530531&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006 May;4(5):621-30. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16678077&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, Langholff W, Londhe A, Sandborn WJ. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol. 2012 Sep;107(9):1409-22. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22890223&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lichtenstein GR, Hanauer SB, Sandborn WJ, Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol. 2009 Feb;104(2):465-83; quiz 464, 484. [270 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19174807&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Terdiman JP, Gruss CB, Heidelbaugh JJ, Sultan S, Falck-Ytter YT, AGA Institute Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-a biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology. 2013 Dec;145(6):1459-63. [2 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24267474&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Travis SP, Stange EF, Lémann M, Oresland T, Chowers Y, Forbes A, D'Haens G, Kitis G, Cortot A, Prantera C, Marteau P, Colombel JF, Gionchetti P, Bouhnik Y, Tiret E, Kroesen J, Starlinger M, Mortensen NJ, European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut. 2006 Mar;55 Suppl 1:i16-35. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16481629&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="3022" OrdBy="110" ID="570" Name="Primary Health Components" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Inflammatory bowel disease (IBD); corticosteroid sparing therapy; prednisone&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="23" OrdBy="120" ID="571" Name="Denominator Description" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;All patients aged 18 years and older with a diagnosis of inflammatory bowel disease (IBD) (see the related &quot;Denominator Inclusions/Exclusions&quot; field)&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="24" OrdBy="130" ID="572" Name="Numerator Description" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patients prescribed a corticosteroid sparing therapy (e.g., thiopurines, methotrexate, or biologic agents) (see the related &quot;Numerator Inclusions/Exclusions&quot; field)&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="573" OrdBy="140" Name="Evidence Supporting the Measure">
    <Field FieldID="3027" OrdBy="150" ID="574" Name="Type of Evidence Supporting the Criterion of Quality for the Measure" Type="picklist-choice">
      <FieldValue Value="A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence" />
      <FieldValue Value="A formal consensus procedure, involving experts in relevant clinical, methodological,  public health and organizational sciences" />
      <FieldValue Value="One or more research studies published in a National Library of Medicine (NLM) indexed, peer-reviewed journal" />
    </Field>
    <Field FieldID="3501" OrdBy="160" ID="575" Name="Additional Information Supporting Need for the Measure" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="3072" OrdBy="180" ID="577" Name="Extent of Measure Testing" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="580" OrdBy="210" Name="State of Use of the Measure">
    <Field FieldID="3029" OrdBy="220" ID="581" Name="State of Use" Type="picklist-one">
      <FieldValue Value="Current routine use" />
    </Field>
    <Field FieldID="3030" OrdBy="230" ID="582" Name="Current Use" Type="picklist-choice-3">
      <FieldValue Value="not defined yet" />
    </Field>
  </Section>
  <Section SecID="583" OrdBy="240" Name="Application of the Measure in its Current Use">
    <Field FieldID="3031" OrdBy="250" ID="584" Name="Measurement Setting" Type="picklist-choice">
      <FieldValue Value="Ambulatory/Office-based Care" />
    </Field>
    <Field FieldID="3032" OrdBy="260" ID="585" Name="Professionals Involved in Delivery of Health Services" Type="picklist-choice-3">
      <FieldValue Value="not defined yet" />
    </Field>
    <Field FieldID="3033" OrdBy="270" ID="586" Name="Least Aggregated Level of Services Delivery Addressed" Type="picklist-one">
      <FieldValue Value="Individual Clinicians or Public Health Professionals" />
    </Field>
    <Field FieldID="3505" OrdBy="280" ID="587" Name="Statement of Acceptable Minimum Sample Size" Type="picklist-one">
      <FieldValue Value="Specified" />
    </Field>
    <Field FieldID="41" OrdBy="290" ID="588" Name="Target Population Age" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Age greater than or equal to 18 years&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="42" OrdBy="300" ID="589" Name="Target Population Gender" Type="picklist-one">
      <FieldValue Value="Either male or female" />
    </Field>
  </Section>
  <Section SecID="660" OrdBy="310" Name="National Strategy for Quality Improvement in Health Care">
    <Field FieldID="3522" OrdBy="320" ID="661" Name="National Quality Strategy Aim" Type="text">
      <FieldValue Value="&lt;ul&gt;&lt;li&gt;Better Care&lt;/li&gt;&lt;/ul&gt;" />
    </Field>
    <Field FieldID="3525" OrdBy="330" ID="662" Name="National Quality Strategy Priority" Type="text">
      <FieldValue Value="&lt;ul&gt;&lt;li&gt;Prevention and Treatment of Leading Causes of Mortality&lt;/li&gt;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="590" OrdBy="340" Name="Institute of Medicine (IOM) National Health Care Quality Report Categories">
    <Field FieldID="3163" OrdBy="350" ID="591" Name="IOM Care Need" Type="picklist-choice">
      <FieldValue Value="Living with Illness" />
    </Field>
    <Field FieldID="3164" OrdBy="360" ID="592" Name="IOM Domain" Type="picklist-choice">
      <FieldValue Value="Effectiveness" />
    </Field>
  </Section>
  <Section SecID="593" OrdBy="370" Name="Data Collection for the Measure">
    <Field FieldID="3506" OrdBy="380" ID="594" Name="Case Finding Period" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The reporting period (January 1 through December 31)&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="3054" OrdBy="390" ID="595" Name="Denominator Sampling Frame" Type="picklist-one">
      <FieldValue Value="Patients associated with provider" />
    </Field>
    <Field FieldID="3057" OrdBy="400" ID="598" Name="Denominator (Index) Event or Characteristic" Type="picklist-choice">
      <FieldValue Value="Clinical Condition" />
      <FieldValue Value="Encounter" />
      <FieldValue Value="Patient/Individual (Consumer) Characteristic" />
    </Field>
    <Field FieldID="3058" OrdBy="410" ID="599" Name="Denominator Time Window" Type="picklist-choice-3">
      <FieldValue Value="not defined yet" />
    </Field>
    <Field FieldID="55" OrdBy="420" ID="596" Name="Denominator Inclusions/Exclusions" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Inclusions &lt;/strong&gt;&lt;br /&gt;&#xA;All patients aged 18 years and older with a diagnosis of inflammatory bowel disease (IBD)&lt;/p&gt;&#xA;&lt;p&gt;&lt;em&gt;Denominator Criteria (Eligible Cases)&lt;/em&gt;:&lt;/p&gt;&#xA;&lt;p&gt;Patients aged greater than or equal to 18 years on date of encounter &lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;AND&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;p&gt;Diagnosis for IBD (International Classification of Diseases, Tenth Revision, Clinical Modification [ICD-10-CM] codes): K50.00, K50.011, K50.012, K50.013, K50.014, K50.018, K50.019, K50.10, K50.111, K50.112, K50.113, K50.114, K50.118, K50.119, K50.80, K50.811, K50.812, K50.813, K50.814, K50.818, K50.819, K50.90, K50.911, K50.912, K50.913, K50.914, K50.918, K50.919, K51.00, K51.011, K51.012, K51.013, K51.014, K51.018, K51.019, K51.20, K51.211, K51.212, K51.213, K51.214, K51.218, K51.219, K51.30, K51.311, K51.312, K51.313, K51.314, K51.318, K51.319, K51.40, K51.411, K51.412, K51.413, K51.414, K51.418, K51.419, K51.50, K51.511, K51.512, K51.513, K51.514, K51.518, K51.519, K51.80, K51.811, K51.812, K51.813, K51.814, K51.818, K51.819, K51.90, K51.911, K51.912, K51.913, K51.914, K51.918, K51.919 &lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;AND&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;p&gt;Patient encounter during the reporting period (refer to the original measure documentation for specific Current Procedural Terminology [CPT] codes)&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;AND&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;p&gt;Patient who has received or is receiving corticosteroids* greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills within the last twelve months: G9467&lt;/p&gt;&#xA;&lt;p class=&quot;Note&quot;&gt;*&lt;em&gt;Corticosteroids&lt;/em&gt;: Prednisone equivalents used expressly for the treatment of IBD and not for other indications (including premedication before anti-TNF [tumor necrosis factor] therapy, non-IBD indications) can be determined using the following: 1 mg of prednisone = 1 mg of prednisolone; 5 mg of cortisone; 4 mg of hydrocortisone; 0.8 mg of triamcinolone; 0.8 mg of methylprednisolone; 0.15 mg of dexamethasone; 0.15 mg of betamethasone. &lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;Exclusions &lt;/strong&gt;&lt;br /&gt;&#xA;None&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="3507" OrdBy="430" ID="597" Name="Exclusions/Exceptions" Type="picklist-choice-4">
      <FieldValue Value="not defined yet" />
    </Field>
    <Field FieldID="59" OrdBy="440" ID="600" Name="Numerator Inclusions/Exclusions" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Inclusions &lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;Patients prescribed a corticosteroid sparing therapy (e.g., thiopurines, methotrexate, or biologic agents) &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Exclusions&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Documentation of medical reason(s) for not treating with corticosteroid sparing therapy (e.g., benefits of continuing steroid therapy outweigh the risk of continuing steroid therapy or initiating steroid sparing therapy, patient is receiving the first course of corticosteroids for the treatment of inflammatory bowel disease [IBD]) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Documentation of patient reason(s) for not treating with corticosteroid sparing therapy (e.g., patient refuses to initiate steroid sparing therapy) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="3061" OrdBy="450" ID="601" Name="Numerator Search Strategy" Type="picklist-one">
      <FieldValue Value="Fixed time period or point in time" />
    </Field>
    <Field FieldID="3062" OrdBy="460" ID="602" Name="Data Source" Type="picklist-many">
      <FieldValue Value="Administrative clinical data" />
      <FieldValue Value="Registry data" />
    </Field>
    <Field FieldID="3065" OrdBy="470" ID="603" Name="Type of Health State" Type="picklist-one">
      <FieldValue Value="Does not apply to this measure" />
    </Field>
    <Field FieldID="3066" OrdBy="480" ID="604" Name="Instruments Used and/or Associated with the Measure" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="605" OrdBy="490" Name="Computation of the Measure">
    <Field FieldID="3508" OrdBy="500" ID="606" Name="Measure Specifies Disaggregation" Type="picklist-one">
      <FieldValue Value="Does not apply to this measure" />
    </Field>
    <Field FieldID="3067" OrdBy="520" ID="608" Name="Scoring" Type="picklist-many">
      <FieldValue Value="Rate/Proportion" />
    </Field>
    <Field FieldID="3068" OrdBy="530" ID="609" Name="Interpretation of Score" Type="picklist-one">
      <FieldValue Value="Desired value is a higher score" />
    </Field>
    <Field FieldID="3090" OrdBy="540" ID="610" Name="Allowance for Patient or Population Factors" Type="picklist-choice-3">
      <FieldValue Value="not defined yet" />
    </Field>
    <Field FieldID="3070" OrdBy="560" ID="612" Name="Standard of Comparison" Type="picklist-choice-3">
      <FieldValue Value="not defined yet" />
    </Field>
  </Section>
  <Section SecID="615" OrdBy="590" Name="Identifying Information">
    <Field FieldID="73" OrdBy="600" ID="616" Name="Original Title" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Measure #270: inflammatory bowel disease (IBD): preventive care: corticosteroid sparing therapy.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="74" OrdBy="610" ID="617" Name="Measure Collection Name" Type="text">
      <FieldValue Value="Inflammatory Bowel Disease" />
    </Field>
    <Field FieldID="16" OrdBy="650" ID="621" Name="Submitter" Type="orglist">
      <FieldValue Value="American Gastroenterological Association - Medical Specialty Society" />
    </Field>
    <Field FieldID="17" OrdBy="660" ID="622" Name="Developer" Type="orglist-p">
      <FieldValue Value="American Gastroenterological Association - Medical Specialty Society" />
      <FieldValue Value="Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration" />
    </Field>
    <Field FieldID="79" OrdBy="670" ID="623" Name="Funding Source(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="80" OrdBy="680" ID="624" Name="Composition of the Group that Developed the Measure" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="81" OrdBy="690" ID="625" Name="Financial Disclosures/Other Potential Conflicts of Interest" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="3083" OrdBy="720" ID="628" Name="Measure Initiative(s)" Type="picklist-many">
      <FieldValue Value="Physician Quality Reporting System" />
    </Field>
    <Field FieldID="19" OrdBy="730" ID="629" Name="Adaptation" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This measure was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="3086" OrdBy="740" ID="630" Name="Date of Most Current Version in NQMC" Type="date">
      <FieldValue Value="2015 Dec" />
    </Field>
    <Field FieldID="3511" OrdBy="750" ID="631" Name="Measure Maintenance" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="3512" OrdBy="760" ID="632" Name="Date of Next Anticipated Revision" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;2017&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="20" OrdBy="770" ID="633" Name="Measure Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the measure.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="14" OrdBy="780" ID="634" Name="Measure Availability" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Source not available electronically.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For more information, contact the American Gastroenterological Association (AGA) at 4930 Del Ray Avenue, Bethesda, MD 20814; Phone: 301-654-2055; Fax: 301-654-5920; E-mail: &lt;a href=&quot;mailto:measures@gastro.org&quot;&gt;measures@gastro.org&lt;/a&gt;; Web site: &lt;a href=&quot;http://www.gastro.org/&quot; title=&quot;AGA Web site&quot;&gt;www.gastro.org&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="87" OrdBy="800" ID="636" Name="NQMC Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NQMC measure summary was completed by ECRI Institute on March 14, 2016. The information was verified by the measure developer on March 29, 2016.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="88" OrdBy="810" ID="637" Name="Copyright Statement" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NQMC summary is based on the original measure, which is subject to the measure developer's copyright restrictions.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Measures are not clinical guidelines, do not establish a standard of medical care, and have not been tested for all potential applications. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;Commercial uses of the Measures require a license agreement between the user and the American Medical Association (AMA), (on behalf of the Physician Consortium for Performance Improvement&amp;reg; [PCPI&amp;reg;]) or American Gastroenterological Association (AGA). Neither the AMA, AGA, PCPI, nor its members shall be responsible for any use of the Measures. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;The AMA's and PCPI's significant past efforts and contributions to the development and updating of the Measures is acknowledged. AGA is solely responsible for the review and enhancement (&quot;Maintenance&quot;) of the Measures as of June 30, 2014&lt;/strong&gt;. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;AGA encourages use of the Measures by other health care professionals, where appropriate. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;THE MEASURES AND SPECIFICATIONS ARE PROVIDED &quot;AS IS&quot; WITHOUT WARRANTY OF ANY KIND. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&amp;copy;2015 American Medical Association and American Gastroenterological Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, AGA, the PCPI and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT&amp;reg;) or other coding contained in the specifications. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;CPT&amp;reg; contained in the Measures specifications is copyright 2004-2014 American Medical Association. LOINC&amp;reg; copyright 2004-2013 Regenstrief Institute, Inc. SNOMED CLINICAL TERMS (SNOMED CT&amp;reg;) copyright 2004-2013 College of American Pathologists. All Rights Reserved.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="641" OrdBy="850" Name="Production">
    <Field FieldID="1" OrdBy="1366" ID="562" Name="Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American Gastroenterological Association (AGA). Inflammatory bowel disease (IBD): preventive care: corticosteroid sparing therapy. Bethesda (MD): American Gastroenterological Association (AGA); 2015 Dec 18. 7 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
  </Section>
  <Section SecID="99999" OrdBy="99999" Name="Disclaimer">
    <Field FieldID="99999" OrdBy="99999" ID="99999" Name="NQMC Disclaimer" Type="text">
      <FieldValue Value="&lt;p&gt;The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the &lt;a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;&gt;NQMC Inclusion Criteria&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding measure content are directed to contact the measure developer.&lt;/p&gt;" />
    </Field>
  </Section>
</Version>